BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Collbio Limited Purchases Assets of Angel Biomedical and Secures Major Contract


3/18/2013 11:21:19 AM

Glasgow, March 18th: Collbio, a new company set up by leading life science financiers Diagnostic Capital Ltd, together with former senior management team members Stewart White and Ross Andrews, is pleased to announce that it has acquired the assets of Angel Biomedical Limited.

From its site in Glasgow, comprising both Grade C and Grade B clean rooms, Collbio will focus on manufacturing medical grade collagen components for the regenerative medicine, in-vitro diagnostics and medical device markets.

Stewart White, who becomes CEO of the new company, commented “The growing requirement for collagen worldwide as an established biomaterial across a wide range of therapeutic and diagnostic applications presents exciting opportunities for Collbio Limited. We have already secured our first major contract in the form of a supply agreement with US-based Cardium Therapeutics for the manufacture of formulated collagen for Cardium’s FDA cleared Excellagen® product.”

Alex Clarkson, principal at Diagnostic Capital agreed: “The underlying strength of the collagen business in particular led to our involvement. With the new set-up and financing in place we believe the business is extremely well placed to become a lead provider for customers in both established and growing markets.”

No financial details were disclosed.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES